Cysteine linked nanobody dimers

Patent metadata

Field	Value
Publication number	US-11426468-B2
Application number	US-201515536751-A
Country	US
Kind code	B2
Filing date	Dec 18, 2015
Priority date	Dec 19, 2014
Publication date	Aug 30, 2022
Grant date	Aug 30, 2022

Abstract

The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.

First claim

The invention claimed is:

1. A method of killing a cancer cell having a Receptor Tyrosine Kinase on its surface, the method comprising contacting the cancer cell with a polypeptide-drug conjugate, wherein the polypeptide-drug conjugate comprises:
(i) a dimer comprising: a first polypeptide comprising at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension consisting of 2 to 10 amino acids and comprising a cysteine moiety, wherein the most C-terminal amino acid of the first polypeptide is not cysteine; and a second polypeptide comprising at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension consisting of 2 to 10 amino acids and comprising a cysteine moiety, wherein the most C-terminal amino acid of the second polypeptide is not cysteine; and
(ii) a cytotoxic drug conjugated to the dimer;
wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety in the C-terminal extension of said first polypeptide and the cysteine moiety in the C-terminal extension of said second polypeptide; and said disulfide bond between the cysteine moiety in the C-terminal extension of said first polypeptide and the cysteine moiety in the C-terminal extension of said second polypeptide is the only intermolecular disulfide bond present in the dimer, and
wherein at least said first polypeptide binds to the Receptor Tyrosine Kinase on the surface of the cancer cell, and upon binding is capable of being internalized by the cancer cell.

2. The method according to claim 1 , wherein the C-terminal extension of the first polypeptide or the second polypeptide consists of 6, 5, 4, 3, or 2 amino acid residue(s).

3. The method according to claim 1 , wherein said first polypeptide and said second polypeptide are identical.

4. The method according to claim 1 , wherein said first polypeptide and said second polypeptide are different.

5. The method according to claim 1 , wherein the cytotoxic drug is chosen from the group consisting of cytostatic agents; cytotoxic agents; chemotherapeutic agents; growth inhibitory agents; toxins, optionally an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof; toxin moieties; and radioactive isotopes.

6. The method according to claim 1 , wherein the Receptor Tyrosine Kinase is an epidermal growth factor receptor.

Assignees

• Ablynx Nv

Inventors

• Janssen Daniel
• Schotte Peter
• Descamps Francis
• Boutton Carlo
• Casteels Peter

Classifications

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K2317/569

  Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title

• A61K47/6843

  the antibody targeting a material from animals or humans · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A61P35/04

  specific for metastasis · CPC title